Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Ovid Therapeutics FCF Yield % Related Terms
Ovid Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1OT vs ARTV, CCCC, RZLT: FCF Yield % Comparison
For the Biotechnology subindustry, Ovid Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (FRA:1OT) has a FCF Yield % of -8.99 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #686 out of 1409 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Ovid Therapeutics' FCF Yield % too high?
Ovid Therapeutics' current FCF Yield % is -8.99. Based on the distribution chart, Ovid Therapeutics ranks #686 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' FCF Yield % compare to ARTV and CCCC?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #686 out of 1409 companies for FCF Yield %. This puts Ovid Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current FCF Yield % is -8.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (FRA:1OT) is currently considered Possible Value Trap. The stock's GF Value™ is €6.53, compared to a current price of €2.10 — trading 67.8% below its estimated fair value. The current FCF Yield % is -8.99. Ovid Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Ovid Therapeutics (FRA:1OT), the current FCF Yield % is -8.99 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (FRA:1OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued.
The current stock price of €2.10 is trading 67.8% below its estimated GF Value™ of €6.53.
GuruFocus considers Ovid Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:1OT:
FCF Yield %: -8.99
GF Value™: €6.53 vs. price of €2.10 (67.8% below fair value)
No single metric tells the full story. See the FRA:1OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
51GF Score
Get the complete analysis for FRA:1OT
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1OT has been successfully added to your 
